After four years at the UK's HealthTech & Medicines KTN
Daniel Smith has rejoined Cobra Biologics as Chief Scientific Officer. He takes responsibility for developing scientific excellence across the Group and enhancing Cobra’s DNA, virus, microbial and mammalian proteins research and development.
Smith has spent the last four years with the bioProcess UK team at the HealthTech & Medicines Knowledge Transfer Network (KTN) as a Knowledge Transfer Manager. He also delivered a number of projects enhancing industrial and academic collaboration as well as innovation in bioprocessing as a Senior Technologist.
Prior to the KTN, Smith gained his industrial experience at Cobra in a variety of roles progressing from Senior Scientist to Commercial Scientific Development Manager.
Peter Coleman, CEO at Cobra Biologics, said: 'This is a significant appointment for Cobra and I am personally very pleased that Dan has decided to return to Cobra as our new CSO. He has a tremendous enthusiasm for science and its application in our industry and from working with him previously, I firmly believe he has experience and ability to further establish Cobra as a leading scientific organisation.'